Miltefosine

DB09031ApprovedInvestigationalWithdrawnSmall moleculeAntileishmanial

Miltefosine is an antileishmanial agent used to treat leishmaniasis, a group of disease caused by parasites of the Leishmania type. Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent.

Chemical structure of Miltefosine
Mechanism
Curator reviewed
Primary indication
For the treatment of mucosal (caused by Leishmania braziliensis), cutaneous (caused by L. braziliensis, L. guyanensis, and L. panamensis), and visceral leishmaniasis (caused by L. donovani).Curator reviewed · 4 structured indications
Formula / weight
C21H46NO4P · 407.576 g/mol (avg)
First approval
United States, 2014
Also known as
HDPC · Hexadecylphosphocholine · Hexadecylphosphorylcholine · Monohexadecylphosphocholine · Monohexadecylphosphorylcholine
Code names
D-18506

Resolves to

Structure
InChIKeyPQLXHQMOHUQAKB-UHFFFAOYSA-NSMILESCCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C
Transporters

What you can answer from here — as of September 28, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
56Drug interactionsStructured to mechanism, not free text
Sign in
37Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
7Marketed productsAcross 3 countries and 6 labellers
Sign in
1ATC codeIncluding every combination product, plus 14 drug categories
Sign in
13+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Miltefosine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account